“Demographics, Prior Therapies, and Reasons for Cemiplimab Treatment: Prospective CemiplimAb-rwlc Survivorship and Epidemiology (C.A.S.E.) Study in Patients with Advanced Cutaneous Squamous Cell Carcinoma”, J of Skin, vol. 4, no. 6, p. s125, Oct. 2020, doi: 10.25251/skin.4.supp.125.